LLY · 10-Q · 2026Q2 · Full report
Guidance and Outlook
ELI LILLY & Co · 2026-08-05 · Importance 40 · Surprise 42 · In source text
Lilly expects near-term financial performance to depend partly on potential regulatory approvals for orforglipron and the pace of demand and uptake through new incretin channels and markets. The company specifically identifies U.S. Medicare access for Zepbound and Foundayo as an important variable. Lilly cautions that channel or demand-driven incretin volume fluctuations can disproportionately affect results in any period, while longer-term growth depends on maintaining competitive positioning and delivering further innovations.
Key facts
- The company expects near-term financial performance will be impacted by timing of additional potential regulatory approvals for orforglipron and demand and pace of uptake in new incretin channels and markets, including U.S. Medicare for Zepbound and Foundayo. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | probable | — | The company expects near-term financial performance will be impacted by timing of additional potential regulatory approvals for… |